# Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

> **NCT02821910** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
- **DRUG:** 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
- **DRUG:** High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
- **DRUG:** 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR
- **DRUG:** Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
- **DRUG:** 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR

## Key facts

- **NCT ID:** NCT02821910
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-20
- **Primary completion:** 2016-10-01
- **Final completion:** 2016-10-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02821910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02821910, "Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02821910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*